Edgar Filing: LINDAHL RICHARD S - Form 4

LINDAHL F	RICHARD S										
Form 4											
February 28,	2019										
FORM 4 UNITED STATES SECURITIES AND										PPROVAL	
	UNITE	Washington, D.C. 20549								3235-0287	
Check th if no long subject to Section 1 Form 4 o	ger STATI 6.									Expires:January 31, 2005Estimated average burden hours per response0.5	
Form 5 obligation may cont See Instru 1(b).	ns Section 1	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section									
(Print or Type I	Responses)										
1. Name and Address of Reporting Person <u>*</u> LINDAHL RICHARD S			2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]				-	5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Check					k all applicable)			
. ,	SSIONAL DR	. ,	(Month/Da 02/26/20	ay/Year)	libuetton			Director X_Officer (give below) EVP, Ch		6 Owner er (specify fficer	
	(Street)	(Street) 4. If Amendmen Filed(Month/Day			-			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
GAITHERS	BURG, MD 2	0879						Person	Aore than One Ro	eporting	
(City)	(State)	(Zip)	Table	e I - Non-De	erivative S	lecuri	ties Ac	quired, Disposed o	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	any		emed on Date, if /Day/Year)	3.4. SecuritiesTransactionAcquired (A) orCodeDisposed of (D)(Instr. 8)(Instr. 3, 4 and 5))	SecuritiesIBeneficially(OwnedI	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	`		
Common Stock (1)	02/26/2019			А	5,081 (2)	А	\$0	16,615	D		
Common Stock	02/26/2019			А	5,081 (3)	А	\$0	21,696	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: LINDAHL RICHARD S - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 61.01	02/26/2019		A	20,321	<u>(4)</u>	02/25/2026	Common Stock	20,321

Reporting Owners

Reporting Owner Name / Address	Relationships						
r	Director	10% Owner	Officer	Other			
LINDAHL RICHARD S 400 PROFESSIONAL DRIVE, SUITE 400 GAITHERSBURG, MD 20879			EVP, Chief Financial Officer				
Signatures							
/s/ S. Scott Lieberman, Attorney-in-fact	02/28/2019						

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated.

These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant,(2) assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to(3) receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period.

(4) Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.